Indaptus Therapeutics (NASDAQ:INDP) Announces Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Indaptus Therapeutics (NASDAQ:INDP) released its earnings results on Monday. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07, Zacks reports.

Indaptus Therapeutics Price Performance

Shares of Indaptus Therapeutics stock traded up $0.01 during midday trading on Wednesday, hitting $1.68. The company had a trading volume of 2,931 shares, compared to its average volume of 45,080. Indaptus Therapeutics has a 1-year low of $1.56 and a 1-year high of $4.08. The business’s 50 day simple moving average is $2.17 and its two-hundred day simple moving average is $2.16. The stock has a market cap of $14.35 million, a PE ratio of -0.94 and a beta of 1.39.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Indaptus Therapeutics in a research note on Monday, June 17th.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.